rais est heel
rais est follow management project
increment simparica trio sale plu launch plan
new cat dog pain drug overal
est remain larg unchang rais est revenue
ep
catalyst watch near-term potenti fda approv simparica trio
come month clariti whether trio label includ use puppi
manag expect financi guidanc februari
increas out-year project rais ep estim follow
vs guidanc rang
annual ep estim revis figur vs
given management simparica trio guidanc increment sale
stand-alone simparica incl cannib effect rais simparica
franchis project rais global simparica franchis stand-alone
trio revenue estim specif rais
simparica franchis sale revenue
estimate current
addit file eu us felin canin monoclon
antibodi mab candid treat osteoarthr pain product
anticip come market incorpor mab pain
pipelin revenu model project mab pain pipelin cat dog
contribut global sale us int
us int us int
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
exhibit consensu ntm price-to-earnings vs spec pharma average continu trade larg
premium group
exhibit incom statement margin valuat
sg op exp
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
price base earn multipl current price-to-earnings premium vs
roughli line w/ average sinc ipo project ep compound-annual-growth-rate
risk achiev price
long-term margin expans fail materi
new govern regul legisl impact growth
dollar strength rel foreign currenc caus fx-driven financi shortfal
